We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

68 hedge funds and large institutions have $185M invested in CytomX Therapeutics in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

85% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 13

46.31% more ownership

Funds ownership: 0% → 46.31% (+46%)

10% more funds holding

Funds holding: 62 → 68 (+6)

40% less capital invested

Capital invested by funds: $308M → $185M (-$123M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
14
Increased
24
Reduced
13
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$11.2M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.44M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.1M
4
BFA
BlackRock Fund Advisors
California
+$1.1M
5
Morgan Stanley
Morgan Stanley
New York
+$715K

Top Sellers

Rank Fund Capital Flow
1
BA
BlackRock Advisors
Delaware
-$3.89M
2
BI
BVF Inc
California
-$448K
3
ROTUOC
Regents of the University of California
California
-$287K
4
Neuberger Berman Group
Neuberger Berman Group
New York
-$224K
5
RG
Redmile Group
California
-$214K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$60M +$207K +17,090 +0.3%
PI
2
Putnam Investments
Massachusetts
$15M -$64.3K -5,309 -0.4%
DM
3
Deerfield Management
New York
$10.4M – – –
PA
4
Perceptive Advisors
New York
$10.2M +$11.2M +923,763 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$8.75M +$138K +11,353 +1%
TCM
6
Tekla Capital Management
Massachusetts
$8.31M – – –
RG
7
Redmile Group
California
$7.66M -$214K -17,700 -2%
BFA
8
BlackRock Fund Advisors
California
$7.13M +$1.1M +91,073 +16%
VMI
9
VHCP Management II
New York
$6.35M – – –
BI
10
BVF Inc
California
$6.1M -$448K -37,007 -6%
CAM
11
Cormorant Asset Management
Massachusetts
$4.08M – – –
Franklin Resources
12
Franklin Resources
California
$3.67M – – –
State Street
13
State Street
Massachusetts
$3.03M +$55.7K +4,596 +2%
Northern Trust
14
Northern Trust
Illinois
$2.58M +$220K +18,182 +8%
PAG
15
Private Advisor Group
New Jersey
$2.36M +$12K +988 +0.5%
BIT
16
BlackRock Institutional Trust
California
$2.24M +$376K +31,032 +18%
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$2.21M +$2.44M +201,203 New
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.11M +$134K +11,058 +6%
OM
19
Opaleye Management
Massachusetts
$1.87M +$121K +10,000 +6%
CS
20
Candriam SCA
Luxembourg
$1.7M – – –
EAM
21
Eventide Asset Management
Massachusetts
$1.65M – – –
MBT
22
Montecito Bank & Trust
California
$1.61M – – –
CC
23
Casdin Capital
New York
$1.4M – – –
Bank of America
24
Bank of America
North Carolina
$1.3M +$565K +46,666 +65%
Charles Schwab
25
Charles Schwab
California
$1.05M +$290K +23,966 +34%
1
2 3

CTMX Hedge Fund Activity: Q4 2016 in Review

68 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2016, worth a combined $185M — down 40% from $308M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new CTMX positions and 6 closed out — a net gain of 8 holders — while 24 added to existing stakes and 13 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $11.2M. The largest seller was BlackRock Advisors, cutting an estimated $3.89M.

  • 68 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2016, up from 62 in Q3 2016.
  • Funds reported $185M of CytomX Therapeutics stock for Q4 2016, down 40% quarter-over-quarter.
  • 14 funds opened new CytomX Therapeutics positions in Q4 2016 and 6 closed out, a net change of +8 holders.
  • The largest CytomX Therapeutics buyer in Q4 2016 was Perceptive Advisors, an estimated $11.2M added.
  • The largest CytomX Therapeutics seller in Q4 2016 was BlackRock Advisors, an estimated $3.89M sold.

Based on aggregated 13F filings for Q4 2016.